Abstract
Two invasive breast cancer cell lines (MDA-MB-231 and BT-549) were found to be more adherent and have greater migratory capacity on bone marrow fibroblasts than three non-invasive cell lines (MCF-7, T47D and BT-483). Antibodies to the adhesion molecules CD44, E-cadherin, ICAM-1, and integrin chains α2, α3, α4, α5, α6, αv, α1, α3 and α7 failed to inhibit breast cancer cell migration through bone marrow fibroblasts. Inhibitors of matrix metalloproteases, 1, 10-phenanthroline, Ro-9790, TIMP-1 and TIMP-2 were able to attenuate the migration of MDA-MB-231 cells through bone marrow fibroblast monolayers suggesting a role for these enzymes in the migration of breast cancer cells through bone marrow adherent layers. Co-culture of MDA-MB-231 cells and bone marrow fibroblasts resulted in augmentation of the levels of the matrix metalloproteases MMP-1 and MMP-2 in culture supernatants. Soluble factors produced by bone marrow fibroblasts were responsible for the increase in MMP-1 levels. However, maximal MMP-2 production was dependent on direct contract between the breast cancer cells and the bone marrow fibroblasts. Modulation of MMP production by cell–cell contact or soluble factors suggests a mechanism by which breast cancer cells can enhance their ability to invade the bone marrow microenvironment.
Similar content being viewed by others
References
Honig S: Treatment of metastatic disease: Hormonal therapy and chemotherapy. In: Harris J, Lippman M, Morrow M, and Hellman S, (eds) Diseases of the Breast, Lippincott-Raven Publishers, Philadelphia, 1996, pp 669–734
Peters W: Treatment of metastatic disease: High-dose chemotherapy for breast cancer. In: Harris J, Lippman M, Morrow M, and Hellman S, (eds) Diseases of the Breast. Lippincott-Raven Publishers, Philadelphia, 1996, pp 735–743
Ross A, Cooper B, Lazarus H, Mackay W, Moss T, Ciobanu N, Tallman M, Kennedy M, Davidson N, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher R, Herzig R, Klumpp T, Kahn D, Warner N: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques Blood 82: 2605–2610, 1993
Kohn E, Liotta L: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55: 1856–1862, 1995
Stetler-Stevenson W, Aznavoorian S, Liotta L: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9: 541–573, 1993
Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, Sowa M, Hirakawa-YS, Chung K: Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 4: 73–77, 1999
Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T: Expression of matrix metalloproteinases (MMP-1 and-2) and their inhibitors (TIMP-1,-2 and-3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 77: 2239–2245, 1998
Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273–282, 1996
Aust G, Hofmann A, Laue S, Rost A, Kohler T, Scherbaum W: Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messanger-RNA and protein. Thyroid 7: 713–724, 1997
Aho S, Rouda S, Kennedy SH, Qin H, Tan EM: Regulation of human interstitial collagenase (matrix metalloproteinase-1) promotor activity by fibroblast growth factor. Eur J Biochem 247: 503–510, 1997
Nutt J, Lunec J: Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer 32A: 2127–2135, 1996
Brenneisen P, Wlaschek M, Wenk J, Blaudschun R, Hinrichs R, Dissemond J, Krieg T, Scharffetter-Kochanek K: Ultraviolet-B induction of interstitial collagenase and stromelyin-1 occurs in human dermal fibroblasts via an autocrine interleukin-6-dependent loop. FEBS Lett 449: 36–40, 1999
Rao V, Singh R, Delimont D, Finnell R, Bridge J, Neff J, Garvin B, Pickering D, Sanger W, Buehler B, Schaefer G: Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 14: 291–300, 1999
Piedagnel R, Murphy G, Ronco P, Lelongt B: Matrix metalloproteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. J Biol Chem 274: 1614–1620, 1999
Kubota S, Ito H, Ishibashi Y, Seyama Y: Anti-α3 integrin antibody induces the activated form of matrix metalloprotease-2 (MMP-2) with concomitant stimulation of invasion through matrigel by human rhabdomyosarcoma cells. Int J Cancer 70: 106–111, 1997
Kortlepel K, Bendall L, Gottlieb D: Adhesion molecule expression on human myeloid leukemic cells: Regulation by growth factors. Leukemia 7: 1174–1179, 1993
Bendall LJ, Kortlepel K, Gottlieb DJ: Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta 1 and beta 2 integrin mechanisms. Blood 82: 3125–3132, 1993
Gu B, Bendall LJ, Wiley JS: Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92: 946–951, 1998
Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239–3245, 1987
Clarke R: Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice Induction of MMP-1 and MMP-2 by co-culture 115 and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39: 69–86, 1996
Bae SN, Arand G, Azzam H, Pavasant P, Torri J, Frandsen TL, Thompson EW: Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigelbased in vitro assays. Breast Cancer Res Treat 24: 241–255, 1993
Eccles S, Box G, Court W, Bone E, Thomas W, Brown P: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815–2822, 1996
Yoneda T, Sasaki A, Dunstan C, Williams P, Bauss F, De Clerck Y, Mundy G: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. Clin Invest 99: 2509–2517, 1997
Singer C, Marbaix E, Lemoine P, Courtoy P, Eeckhout Y: Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts. Eur J Biochem 259: 40–45, 1999
HIoyhtyIa M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson W, Liotta L, Liang C: Immunohistochemical localisation of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56: 500–505, 1994
Noel A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remacle A, Kebers F, Brown P, Calberg-Bacq CM, Foidart JM: Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 76: 267–273, 1998
Long L, Navab R, Brodt P: Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 58: 3243–3247, 1998
Kobayashi T, Hattori S, Nagai Y, Tajima S, Nishikawa T: Differential regulation of MMP-2 and MMP-9 gelatinases in cultured human keratinocytes. Dermatology 197: 1–5, 1998
Wingrove C, Garr E, Godsland I, Stevenson J: 17 betaoestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1406: 169–174, 1998
Xie B, Laouar A, Huberman E: Autocrine regulation of macrophage differentiation and 92-kDa gelatinase production by tumor necrosis factor-alpha via alpha5 beta1 integrin in HL-60 cells. J Biol Chem 273: 11583–11588, 1998
Esteve P, Tremblay P, Houde M, St-Pierre Y, Mandeville R: In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta 1403: 85–96, 1998
Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T: Regulation of matrix metalloproteinases (MMP-2,-3,-9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139: 1338–1345, 1998
Boyd RS, Balkwill FR: MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer 80: 315–321, 1999
Brooks P, Stromblad S, Sanders L, von Schalscha T, Aimes R, Stetler-Stevenson W, Quigley J, DA C: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683–693, 1996
Ellerbroek S, Fishman D, Kearns A, Bafetti L, Stack M: Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through betal integrin. Cancer Res 59: 1635–1641, 1999
Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK: Characterization of the gene for human Emmprin, a tumor cell surface inducer of matrix metalloproteinases. Gene 220: 99–108, 1998
Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW: Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 59: 947–952, 1999
Hazan RB, Kang L, Whooley BP, Borgen PI: N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 4: 399–411, 1997
Rights and permissions
About this article
Cite this article
Saad, S., Bendall, L.J., James, A. et al. Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 63, 105–115 (2000). https://doi.org/10.1023/A:1006437530169
Issue Date:
DOI: https://doi.org/10.1023/A:1006437530169